These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27696263)

  • 1. Treatment of Relapsed/Refractory Multiple Myeloma.
    Neri P; Bahlis NJ; Paba-Prada C; Richardson P
    Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma: from front-line to relapsed therapies.
    Moreau P; Touzeau C
    Am Soc Clin Oncol Educ Book; 2015; ():e504-11. PubMed ID: 25993216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of multiple myeloma in the relapsed/refractory patient].
    Tabayashi T
    Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines].
    Ozaki S
    Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
    Sonneveld P; De Wit E; Moreau P
    Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
    Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
    Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The next generation of novel therapies for the management of relapsed multiple myeloma.
    Gonsalves WI; Milani P; Derudas D; Buadi FK
    Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies in multiple myeloma.
    El-Amm J; Tabbara IA
    Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
    Kuroda J
    Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current treatment of refractory and relapsed multiple myeloma].
    Sasaki M
    Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in myeloma treatment.
    Schots R
    Transfus Apher Sci; 2011 Apr; 44(2):223-9. PubMed ID: 21349768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment algorithms for multiple myeloma in Japan].
    Ozaki S
    Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
    Vij R
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():45-55. PubMed ID: 25188481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.